This updated systematic review and meta-analysis of randomized and observational studies
published up to April 2023 assessed the relative performance of high-dose inactivated …

Influenza is associated with a substantial health burden, especially in high-risk subjects
such as older adults, frail individuals and those with underlying chronic diseases. In this …

Background Annual influenza vaccination is widely recommended in older adults and other
high-risk groups including patients with cardiovascular disease. The real-world effectiveness …

Influenza affects millions of people worldwide each year and can lead to severe
complications, hospitalizations, and even death, especially among vulnerable populations …

Individuals aged 65 years and above are at increased risk of complications and death from
influenza compared with any other age group. Enhanced vaccines, as the MF59® …

This report updates the 2022–23 recommendations of the Advisory Committee on
Immunization Practices (ACIP) concerning the use of seasonal influenza vaccines in the …

Objectives To evaluate the relative effectiveness of high-dose quadrivalent influenza
vaccine (QIV-HD) versus standard-dose quadrivalent influenza vaccine (QIV-SD) against …

Randomized encouragement trial designs, where participants are randomly assigned to an
opportunity or encouragement to receive treatment instead of to the treatment itself, can be …

After the initial randomized clinical trials and emergency use authorization of the COVID-19
vaccines by the US Food and Drug Administration (FDA) during the COVID-19 pandemic …

Aim High‐dose quadrivalent influenza vaccine (QIV‐HD) has been shown to be more
effective than standard‐dose (QIV‐SD) in reducing influenza infection, but whether diabetes …